Eli Lilly lines up metabolic pacts with Evotec, Abbisko as it awaits diabetes med nod from FDA

Eli Lilly is busy making deals days after the J.P. Morgan Healthcare Conference wrapped. The Indianapolis Big Pharma signed collaborations with biopharma partner Evotec in a potentially $1 billion biobucks pact and with Abbisko Therapeutics in a deal worth up to $258 million.